The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Screening and Prostate-Cancer Mortality in a Randomized European Study

På svenska

Author

  • Fritz H. Schroeder
  • Jonas Hugosson
  • Monique J. Roobol
  • Teuvo L. J. Tammela
  • Stefano Ciatto
  • Vera Nelen
  • Maciej Kwiatkowski
  • Marcos Lujan
  • Hans Lilja
  • Marco Zappa
  • Louis J. Denis
  • Franz Recker
  • Antonio Berenguer
  • Liisa Maattanen
  • Chris H. Bangma
  • Gunnar Aus
  • Arnauld Villers
  • Xavier Rebillard
  • Theodorus van der Kwast
  • Bert G. Blijenberg
  • Sue M. Moss
  • Harry J. de Koning
  • Anssi Auvinen
Show all

Summary, in English

Background The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer. Methods We identified 182,000 men between the ages of 50 and 74 years through registries in seven European countries for inclusion in our study. The men were randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control group that did not receive such screening. The predefined core age group for this study included 162,243 men between the ages of 55 and 69 years. The primary outcome was the rate of death from prostate cancer. Mortality follow-up was identical for the two study groups and ended on December 31, 2006. Results In the screening group, 82% of men accepted at least one offer of screening. During a median follow-up of 9 years, the cumulative incidence of prostate cancer was 8.2% in the screening group and 4.8% in the control group. The rate ratio for death from prostate cancer in the screening group, as compared with the control group, was 0.80 (95% confidence interval [CI], 0.65 to 0.98; adjusted P = 0.04). The absolute risk difference was 0.71 death per 1000 men. This means that 1410 men would need to be screened and 48 additional cases of prostate cancer would need to be treated to prevent one death from prostate cancer. The analysis of men who were actually screened during the first round (excluding subjects with noncompliance) provided a rate ratio for death from prostate cancer of 0.73 (95% CI, 0.56 to 0.90). Conclusions PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)

Publishing year

2009

Language

English

Pages

1320-1328

Publication/Series

New England Journal of Medicine

Volume

360

Issue

13

Document type

Journal article

Publisher

Massachusetts Medical Society

Topic

  • Medicinal Chemistry

Status

Published

Research group

  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 0028-4793